Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

NEKTAR THERAPEUTICS

(NKTR)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/18/2019 06/19/2019 06/20/2019 06/21/2019 06/24/2019 Date
35.17(c) 35.34(c) 35.39(c) 34.86(c) 33.89(c) Last
1 211 468 931 515 1 013 327 2 250 698 996 202 Volume
+4.36% +0.48% +0.14% -1.50% -2.78% Change
More quotes
Financials (USD)
Sales 2019 111 M
EBIT 2019 -539 M
Net income 2019 -538 M
Finance 2019 1 409 M
Yield 2019 -
Sales 2020 204 M
EBIT 2020 -483 M
Net income 2020 -436 M
Finance 2020 567 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 41,9x
EV / Sales2020 27,0x
Capitalization 6 076 M
More Financials
Company
Nektar Therapeutics specializes in the research and development of drugs for the treatment of cancer, autoimmune diseases and chronic pain. Net sales break down by source of income as follows: - revenues from licensing and collaboration agreements (91.9%); - product sales (4.6%); - royalties... 
More about the company
Surperformance© ratings of Nektar Therapeutics
Trading Rating : Investor Rating :
More Ratings
Latest news on NEKTAR THERAPEUTICS
06/14NEKTAR THERAPEUTICS : Submission of Matters to a Vote of Security Holders (form ..
AQ
06/13NEKTAR THERAPEUTICS : First-in-Human Data Presented from Phase 1a Study of NKTR-..
PR
06/11NEKTAR THERAPEUTICS : to Host Webcast Conference Call with Immunology Expert for..
PR
05/27NEKTAR THERAPEUTICS : COO Sells $127,895.49 in Stock
AQ
05/25TROVAGENE : Announces Research Collaboration with Nektar Therapeutics to Evaluat..
AQ
05/25NEKTAR THERAPEUTICS : unveils Inheris Biopharma, its new CNS-focused offshoot
AQ
05/25NEKTAR THERAPEUTICS : New Biopharmaceutical Company Launched with Focus on Pain ..
AQ
05/24TROVAGENE : Announces Research Collaboration with Nektar Therapeutics to Evaluat..
AQ
05/23NEKTAR THERAPEUTICS : Announces the Launch of Inheris Biopharma, Inc.
PR
05/21NEKTAR THERAPEUTICS : (NKTR) COO Sells 4,077 Shares of Stock
AQ
More news
Analyst Recommendations on NEKTAR THERAPEUTICS
More recommendations
Sector news : Biotechnology & Medical Research - NEC
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 69,9 $
Spread / Average Target 101%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS3.10%5 937
IQVIA HOLDINGS INC36.58%26 223
LONZA GROUP28.86%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION39.49%17 061
EXACT SCIENCES CORPORATION83.26%13 037